Efficacy of early treatment with infliximab in pediatric Crohn’s disease
Open Access
- 1 January 2010
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (14), 1776-81
- https://doi.org/10.3748/wjg.v16.i14.1776
Abstract
To investigate the effectiveness of early infliximab use for induction and maintenance therapy in pediatric Crohn's disease. We performed a retrospective chart review of 36 patients with Crohn's disease. Ten patients (group A) were treated with mesalamine after induction therapy with oral prednisolone, and 13 patients (group B) were treated with azathioprine after induction therapy with oral prednisolone. Thirteen patients (group C) received infliximab and azathioprine for induction and maintenance therapy for the first year, and were treated with azathioprine after 1 year. All patients were followed for at least 24 mo. Efficacy was determined by the relapse rate using the pediatric Crohn's disease activity index score in each group at 12 and 24 mo. At the 1 year follow-up, the relapse rate (23.1%, 3 of 13 patients) in group C was lower than that (61.5%, 8 of 13 patients) in group B (P = 0.047). At the 2 years follow-up, the relapse rate (38.5%, 5 of 13 patients) in group C was lower than that (76.9%, 10 of 13 patients) in group B (P = 0.047). Adverse events in group C were fewer than in groups A and B. Early induction with infliximab at diagnosis, known as "top-down" therapy, was effective for reducing the relapse rate compared to conventional therapies for at least 2 years.Keywords
This publication has 24 references indexed in Scilit:
- Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel DiseaseGastroenterology, 2008
- Inflammatory Bowel Disease in Children and Adolescents: Recommendations for Diagnosis‐The Porto CriteriaJournal of Pediatric Gastroenterology and Nutrition, 2005
- Tumor necrosis factor-alpha antibody for induction of remission in Crohn's diseaseCochrane Database of Systematic Reviews, 2003
- Lack of common NOD2 variants in Japanese patients with Crohn's diseaseGastroenterology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- The limitations of corticosteroid therapy in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2001
- Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.Inflammatory Bowel Diseases, 2001
- Use of infliximab in the treatment of Crohn's disease in children and adolescentsThe Journal of Pediatrics, 2000
- Assessing activity of pediatric Crohn's disease: Which index to use?Gastroenterology, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997